Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Covid-19 Infection and Hospitalization Rate in Iranian Multiple Sclerosis Patients: What We Know by May 2021 Publisher Pubmed



Naghavi S1 ; Kavosh A2 ; Adibi I3 ; Shaygannejad V1 ; Arabi S4 ; Rahimi M2 ; Mazaheri S2 ; Ashtari F1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran, b. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Multiple Sclerosis and Related Disorders Published:2022


Abstract

Background:: Despite investigations on the effect of disease modifying therapies (DMTs) used in multiple sclerosis (MS) on coronavirus disease 2019 (COVID-19); there are still controversies. Objective:: We designed this study to evaluate the epidemiological features of covid-19 in a large sample of people with MS (pwMS) in Isfahan, Iran, as well as the association between DMTs, risk of COVID-19 infection and hospitalization. Methods:: In an observational pwMS, we interviewed subjects on their MS and COVID-19 history. Results:: 3050 subjects were included (74% female) with a mean age of 41.36. 423 (13.8%) had confirmed COVID-19 which shows that pwMS are at a higher risk of infection compared to the general population, No significant relationship was observed in COVID-19 infection when individual drugs. Dimethyl fumarate and rituximab had the lowest and the highest relative risks for hospitalization rate compared to other drugs, respectively. Conclusion:: We found no evidence supporting a higher prevalence of COVID-19 in pwMS compared to the general population. However, our results show pwMS to be more prone to hospitalization compared to the general population, Therefore, it is advised to use safer treatment if possible until complete vaccination, and to postpone the use of rituximab. © 2021
Related Docs
View other Related Docs
1. The Prevalence of Covid-19 Infection in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Neurological Sciences (2021)
2. Risk Factors of Severe Covid-19 in People With Multiple Sclerosis : A Systematic Review and Meta-Analysis, Revue Neurologique (2022)
3. Covid-19 Among Patients With Multiple Sclerosis a Systematic Review, Neurology: Neuroimmunology and NeuroInflammation (2021)
4. Characteristics of Covid-19 in Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)
5. Disease-Modifying Therapies, Outcomes, Risk Factors and Severity of Covid-19 in Multiple Sclerosis: A Menactrims Registry Based Study, Multiple Sclerosis and Related Disorders (2024)
6. Predictors of Catching Covid-19 Infection During Pandemic Stage in Patients With Multiple Sclerosis (Ms), International Journal of Preventive Medicine (2022)
7. A Multi-Centre Longitudinal Study Analysing Multiple Sclerosis Disease-Modifying Therapy Prescribing Patterns During the Covid-19 Pandemic, Journal of Neurology (2024)
8. Effect of Multiple Sclerosis Disease-Modifying Therapies on the Real-World Effectiveness of Two Doses of Bbibp-Corv (Sinopharm) Vaccine, Journal of the Neurological Sciences (2023)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (59)
Masoud Etemadifar (52)
Other Related Docs
9. Outcome of Covid-19 Infection in Multiple Sclerosis Patients Receiving Disease-Modifying Therapies, Journal of Research in Medical Sciences (2021)
10. The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations During the Covid-19 Pandemic, Biomolecules (2021)
11. Multiple Sclerosis Is Associated With Worse Covid-19 Outcomes Compared to the General Population: A Population-Based Study, Multiple Sclerosis and Related Disorders (2023)
12. Covid-19 Susceptibility and Outcomes Among Patients With Neuromyelitis Optica Spectrum Disorder (Nmosd): A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2022)
13. Assessment of Mental Health, Knowledge, and Attitude of Patients With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Response to 2019 Novel Coronavirus, Neurological Sciences (2021)
14. Prevalence and Incidence of Multiple Sclerosis in Isfahan, Iran Between 1996 and 2021: A Population-Based Study, Multiple Sclerosis and Related Disorders (2024)
15. Impact of the Covid-19 Pandemic on the Psychological Status and Cortisol Level of Multiple Sclerosis Patients, Neuropsychological Rehabilitation (2023)
16. Risk and Severity of Sars-Cov-2 Reinfection Among Patients With Multiple Sclerosis Vs. the General Population: A Population-Based Study, BMC Neurology (2022)
17. Does Covid-19 Increase the Long-Term Relapsing-Remitting Multiple Sclerosis Clinical Activity? a Cohort Study, BMC Neurology (2022)
18. Fear and Anxiety in Patients With Multiple Sclerosis During Covid-19 Pandemic; Report of an Iranian Population, Multiple Sclerosis and Related Disorders (2021)
19. The Impact of Covid-19 Pandemic on Neuromyelitis Optica Disorder Patients, After One Year, Caspian Journal of Neurological Sciences (2022)
20. Can Coronavirus Disease 2019 (Covid-19) Trigger Exacerbation of Multiple Sclerosis? a Retrospective Study, Multiple Sclerosis and Related Disorders (2021)
21. Covid-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight With No Bystander Effect?, Multiple Sclerosis and Related Disorders (2021)
22. Epidemiology of Multiple Sclerosis in Iran: A Systematic Review, European Neurology (2013)
23. Sharp Increase in the Incidence and Prevalence of Multiple Sclerosis in Isfahan, Iran, Multiple Sclerosis Journal (2011)
24. A Case-Control Study of Risk Factors for Multiple Sclerosis in Iran, Multiple Sclerosis Journal (2011)
25. Incidence and Prevalence of Multiple Sclerosis in Persian Gulf Area: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2020)
26. Multiple Sclerosis Epidemiology in Asia and Oceania; a Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2021)
27. Fear of Re-Infection, Relapse, and Anxiety During Covid-19 Pandemic in Patients With Multiple Sclerosis: A Multi-Center Study, Current Journal of Neurology (2023)
28. Multiple Sclerosis (Ms) and Neuromyelitis Optica Spectrum Disorder (Nmosd) Following Covid-19 Vaccines: A Systematic Review, Revue Neurologique (2023)
29. The Prevalence of Myocardial Infarction Among Multiple Sclerosis Patients: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2021)
30. Comparing the Consequences of Covid-19 Vaccination Between Central Nervous System (Cns) Demyelinating Diseases and Other Neurological Disorders, Vaccine (2024)
31. The Correlation Between Rituximab Dose Reduction and Acute Relapses of Neuromyelitis Optica Spectrum Disorder, Lessons From Covid-19 Epidemic, Multiple Sclerosis and Related Disorders (2024)
32. Multiple Sclerosis Disease-Modifying Therapies and Covid-19 Vaccines: A Practical Review and Meta-Analysis, Journal of Neurology, Neurosurgery and Psychiatry (2022)
33. Multiple Sclerosis Relapse After Covid-19 Vaccination: A Case Report-Based Systematic Review, Journal of Clinical Neuroscience (2022)
34. Safety of Sinopharm Vaccine for People With Multiple Sclerosis: Study of Adverse Reactions and Disease Activity, Multiple Sclerosis and Related Disorders (2022)
35. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years, Multiple Sclerosis and Related Disorders (2022)
36. Covid-19 Vaccination Willingness and Acceptability in Multiple Sclerosis Patients: A Cross Sectional Study in Iran, Vaccines (2022)
37. Self-Reported Safety of the Bbibp-Corv (Sinopharm) Covid-19 Vaccine Among Iranian People With Multiple Sclerosis, Human Vaccines and Immunotherapeutics (2022)
38. Infliximab and Intravenous Gammaglobulin in Hospitalized Severe Covid-19 Patients in Intensive Care Unit, Archives of Iranian Medicine (2021)
39. Risk Factors for the Mortality in Hospitalized Patients With Covid-19: A Brief Report, Iranian Journal of Medical Sciences (2021)
40. Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study, Neurology (2022)
41. Favipiravir in the Treatment of Outpatient Covid-19: A Multicenter, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial, Advances in Respiratory Medicine (2023)
42. Neuro-Mucormycosis: Lessons From Covid-19-Associated Cases, Current Journal of Neurology (2023)
43. Rehabilitation, a Necessity in Hospitalized and Discharged People Infected With Covid-19: A Narrative Review, Physical Therapy Reviews (2021)
44. Serum Uric Acid Level in Patients With Relapsing-Remitting Multiple Sclerosis, Journal of Clinical Neuroscience (2013)
45. Favorable Outcome After Covid-19 Infection in a Multiple Sclerosis Patient Initiated on Ocrelizumab During the Pandemic, Multiple Sclerosis and Related Disorders (2020)
46. Ramadan Fasting and Risk of Covid-19, International Journal of Preventive Medicine (2020)
47. Futurology of Covid-19 in Nursing and Cardiovascular Complications; [Futurologia Del Covid-19 En Enfermeria Y Complicaciones Cardiovasculares], Revista Latinoamericana de Hipertension (2023)
48. Anti-Cd20 Therapies for Pediatric-Onset Multiple Sclerosis: A Systematic Review, Multiple Sclerosis and Related Disorders (2024)
49. Th1, Th2 and Th17 Cytokine Profile in Patients With Multiple Sclerosis Following Treatment With Rapamycin, Iranian Journal of Immunology (2016)
50. The Effectiveness of Natalizumab Vs Fingolimod–A Comparison of International Registry Studies, Multiple Sclerosis and Related Disorders (2021)